[Patient with type II membranoproliferative glomerulonephritis: intravitreal bevacizumab therapy for choroidal neovascularization].
Membranoproliferative glomerulonephritis (MPGN) type II is a rare disease characterized by electron dense deposits on the basement membrane in the glomeruli of the kidneys and also in Bruch's membrane of the eye. Although most patients have asymptomatic drusen of the retina choroidal neovascularization can sometimes develop, which can permanently affect visual acuity. We report an unusual case of choroidal neovascularization in a patient with MPGN type II that was successfully treated with a single intravitreal injection of bevacizumab. The 6 months follow-up showed no recurrence of choroidal neovascularization.
Moorfields Eye Hospital, 162 City Road, London, UK.
M
M
Karampelas
N
N
Kopsachilis
J H
JH
Chang
B
B
Pal
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology*; D015432:Glomerulonephritis, Membranoproliferative / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab